Aline Talhouk

Assistant Professor

The University of British Columbia
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (22)

Year:

2026

Background/Objectives: With the rising incidence of obesity-related endometrial cancer, there is renewed interest in physiologic, low-cost approaches to identify women with hormonally active endometrium who may benefit from early preventive interventions. The progesterone challenge test (PCT), an established clinical tool for evaluating amenorrhea, has been previously proposed as a method to detect endometrial pathology. This study systematically evaluated the diagnostic accuracy of the PCT for detecting endometrial hyperplasia, intraepithelial neoplasia, and carcinoma in asymptomatic postmenopausal women to determine its potential role as a physiologic marker of endometrial cancer risk. Methods: A systematic review and meta-analysis were conducted following PRISMA-DTA guidelines. MEDLINE, EMBASE, EBM Reviews, and CINAHL were searched from inception to 20 January 2025, along with ClinicalTrials.gov and grey literature. Eligible studies prospectively evaluated the PCT with endometrial biopsy as the reference standard. Data extraction and risk-of-bias assessment were performed in duplicate. Risk of bias was assessed using QUADAS-2. Pooled sensitivity, specificity, and predictive values were estimated using hierarchical summary receiver operating characteristic models. Results: Nineteen studies (n = 3902) met the inclusion criteria. The pooled sensitivity and specificity of the PCT for detecting endometrial pathology were 95% (95% CI 86–100%) and 87% (76–96%), respectively. The positive predictive value was 32% (95% CI, 16–50%) and the negative predictive value was 100% (100–100%). When endometrial proliferation was included in the target condition, sensitivity decreased to 82%, but positive predictive value increased to 70%. Conclusions: The PCT shows high diagnostic accuracy for identifying estrogen-driven endometrial pathology in asymptomatic postmenopausal women. Re-evaluating this simple, physiologic test as a functional risk-stratification tool could inform precision prevention strategies for endometrial cancer.

Year:

2026

Kaplan–Meier curves of OS in ( A ) main tumor groups ( n = 582)—MBOT, MOC, LGI, and UGI; ( B ) patients with MOC by FIGO stage ( n = 184); ( C ) patients with MOC by pattern of invasion in all stages ( n = 178); and ( D ) patients with stage I MOC ( n = 134), by pattern of invasion.

Year:

2025

Schema of study numbers for each analysis to describe different cohort numbers due to pathology review and missing data. MOC, mucinous ovarian carcinoma; MBOT, mucinous borderline ovarian tumor; LGI, lower gastrointestinal; UGI, upper gastrointestinal; SISH, silver in situ hybridization.

Year:

2025

Heat map of unsupervised clustering analysis. Contains all samples with a concordant pathology diagnosis ( n = 497), with MOC grouped by FIGO stage. Labels show main clusters and diagnoses. Gene-expression values are normalized and logarithm base 2 transformed. dx, diagnosis.

Year:

2025

Background: Ovarian high-grade serous carcinomas (HGSC) comprise four distinct molecular subtypes based on mRNA expression patterns, with differential survival. Understanding risk factor associations is important to elucidate the etiology of HGSC. We investigated associations between different epidemiologic risk factors and HGSC molecular subtypes. Methods: We pooled data from 11 case–control studies with epidemiologic and tumor gene expression data from custom NanoString CodeSets developed through a collaboration within the Ovarian Tumor Tissue Analysis consortium. The PrOTYPE-validated NanoString-based 55-gene classifier was used to assign HGSC gene expression subtypes. We examined associations between epidemiologic factors and HGSC subtypes in 2,070 cases and 16,633 controls using multivariable-adjusted polytomous regression models. Results: Among the 2,070 HGSC cases, 556 (27%) were classified as C1.MES, 340 (16%) as C5.PRO, 538 (26%) as C2.IMM, and 636 (31%) as C4.DIF. The key factors, including oral contraceptive use, parity, breastfeeding, and family history of ovarian cancer, were similarly associated with all subtypes. Heterogeneity was observed for several factors. Former smoking [OR = 1.25; 95% confidence interval (CI) = 1.03, 1.51] and genital powder use (OR = 1.42; 95% CI = 1.08, 1.86) were uniquely associated with C2.IMM. History of endometriosis was associated with C5.PRO (OR = 1.46; 95% CI = 0.98, 2.16) and C4.DIF (OR = 1.27; 95% CI = 0.94, 1.71) only. Family history of breast cancer (OR = 1.44; 95% CI = 1.16, 1.78) and current smoking (OR = 1.40; 95% CI = 1.11, 1.76) were associated with C4.DIF only. Conclusions: This study observed heterogeneous associations of epidemiologic and modifiable factors with HGSC molecular subtypes. Impact: The different patterns of associations may provide key information about the etiology of the four subtypes.

Year:

2025

Purpose: Endometrioid ovarian carcinoma (ENOC) is the second most-common type of ovarian carcinoma, comprising 10%–20% of cases. Recently, the study of ENOC has benefitted from comparisons to endometrial carcinomas including defining ENOC with four prognostic molecular subtypes. Each subtype suggests differential mechanisms of progression, although tumor-initiating events remain elusive. There is evidence that the ovarian microenvironment may be critical to early lesion establishment and progression. However, while immune infiltrates have been well studied in high-grade serous ovarian carcinoma, studies in ENOC are limited. Experimental Design: We report on 210 ENOC, with clinical follow-up and molecular subtype annotation. Using multiplex IHC and immunofluorescence, we examine the prevalence of T-cell lineage, B-cell lineage, macrophages, and populations with programmed cell death protein 1 or programmed death-ligand 1 across subtypes of ENOC. Results: Immune cell infiltrates in tumor epithelium and stroma showed higher densities in ENOC subtypes with known high mutation burden ( POLE mut and MMRd). While molecular subtypes were prognostically significant, immune infiltrates were not (overall survival P > 0.2). Analysis by molecular subtype revealed that immune cell density was prognostically significant in only the no specific molecular profile (NSMP) subtype, where immune infiltrates lacking B cells (TIL B minus ) had inferior outcome (disease-specific survival: HR, 4.0; 95% confidence interval, 1.1–14.7; P Conclusions: Subtype stratification is critical for better understanding of ENOC, in particular the distribution and prognostic significance of immune cell infiltrates. The role of B cells in the immune response within NSMP tumors warrants further study.

Year:

2025

Purpose: Endometrioid ovarian carcinoma (ENOC) is the second most-common type of ovarian carcinoma, comprising 10-20% of cases. Recently, the study of ENOC has benefitted from comparisons to endometrial carcinomas (EC) including defining ENOC with four prognostic molecular subtypes. Each subtype suggests differential mechanisms of progression, though tumor initiating events remain elusive. There is evidence that the ovarian microenvironment may be critical to early lesion establishment and progression. However, while immune infiltrates have been well studied in high-grade serous ovarian carcinoma, studies in ENOC are limited. Experimental Design: We report on 210 ENOC, with clinical follow-up and molecular subtype annotation. Using multiplex immunohistochemistry and immunofluorescence, we examine the prevalence of T cell lineage, B cell lineage, macrophages, and populations with PD-1 or PD-L1 across subtypes of ENOC. Results: Immune cell infiltrates in tumor epithelium and stroma showed higher densities in ENOC subtypes with known high mutation burden ( POLE mut and MMRd). While molecular subtypes were prognostically significant, immune infiltrates were not (OS p>0.2). Analysis by molecular subtype revealed that immune cell density was prognostically significant in only the no specific molecular subtype (NSMP) subtype, where immune infiltrates lacking B cells (TIL B minus ) had inferior outcome (DSS HR:4.0 CI 1.1-14.7, p

Year:

2024

Characterization of HGSC with co-loss of RB1 and BRCA . A, GSEA indicating up- and downregulated pathways in tumors according to BRCA and RB1 status. RB1 -alt, RB1 altered; RB1 -wt, RB1 wild-type. B, Boxplots comparing GSVA pathway enrichment scores of the cGAS-STING and Toll-like receptor signaling pathways between molecular subgroups; points represent each sample, boxes show the interquartile range (25th–75th percentiles), central lines indicate the median, and whiskers show the smallest/largest values within 1.5 times the interquartile range. Colored boxes with black points indicate the HRD and/or RB1 altered groups, whereas the gray boxes with gray points indicate the HRP and RB1 wild-type group. P values were calculated using a two-sided Mann–Whitney-Wilcoxon test. Benjamini–Hochberg adjusted P values are shown above each pairwise comparison (*, P P P ≥ 0.05). C, Bubble plot summary of HLA gene expression comparisons using DESeq2 between HGSC tumors grouped by HRD and/or RB1 status as shown. The size of the bubbles corresponds to the negative log 10 Benjamini–Hochberg adjusted P value ( P adj ) and only values with P adj ≤ 0.1 are shown. The color and intensity correspond to the log 2 fold change. Genes are grouped by their classes. D, Proportion of TILs in HGSC tumors grouped by RB1 protein expression and BRCA germline status. χ 2 P value is indicated. E, Proportion of tumors classified as each HGSC molecular subtype ( 13 ) grouped by RB1 expression and BRCA germline status. χ 2 P value is indicated. C4.DIF, C4/differentiated subtype; C2.IMM, C2/immunoreactive subtype; C1.MES, C1/mesenchymal subtype; C5.PRO, C5/proliferative subtype.

Year:

2024

Sensitivity to therapeutic agents in BRCA1 -altered cell lines with RB1 knockout. A, RB1 was knocked out using CRISPR/Cas9 in three patient-derived Australian Ovarian Cancer Study (AOCS) HGSC cell lines with either wild-type or altered BRCA1 ( BRCA1 var) background. Representative Western Blots show protein levels of RB1 and phosphorylated RB1 (pRB1) compared with GAPDH loading control in single-cell cloned, homozygous RB1 wild-type (WT) and knockout (KO) colonies in comparison with heterogeneous populations with a scramble single guide RNA (sgRNA). Independent blots were used for RB1 and pRB1. B, Cell viability was compared between RB1 WT and KO clones following treatment with cisplatin (72 h), paclitaxel (72 h), or olaparib (120 h). Nonlinear regression drug curves are shown; P values are shown in Supplementary Table S18 ( n = 3). Error bars indicate ± SEM; for some values, error bars are shorter than the symbols and thus are not visible. C, Proportion of surviving colonies following 16 days of treatment with cisplatin, paclitaxel, or a combination of both (Cis/Pac; with half of the IC50 determined per drug and cell line respectively) relative to DMF vehicle control ( n = 3 replicates). Data are presented as mean ± SEM. Mean values were compared by Student’s t test (ns, not significant; *, P P

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (69)

Jessica N. McAlpine

Chew Wei Chair Gynecologic Oncology, Division Head

The University of British Columbia

CANADA
View details

Laurence Bernard

McGill University Health Centre

CANADA
View details

Charlie Gourley

University of Edinburgh

UNITED KINGDOM
View details

Sue K. Park

Professor

Seoul National University College of Medicine

SOUTH KOREA
View details

Kathryn Terry

Co-Scientific Director

Boston Children's Hospital

UNITED STATES
View details

Elizabeth Christie

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Timothy Budden

Lecturer

University of Liverpool

UNITED KINGDOM
View details

Beth Karlan

Vice Chair

University of California, Los Angeles

UNITED STATES
View details

Anna Jakubowska

Head

Pomeranian Medical University

POLAND
View details

Lynne Wilkens

Professor

University of Hawaii at Manoa

UNITED STATES
View details

Anthony Swerdlow

Professor of Epidemiology

Institute of Cancer Research Sutton

UNITED KINGDOM
View details

Matthew Wakefield

University of Melbourne

AUSTRALIA
View details

Martin Widschwendter

Professor; Director

University of Innsbruck

AUSTRIA
View details

P. M. Webb

Group Leader

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Martin Köbel

Associate Professor

University of Calgary

CANADA
View details

Estrid V. Hoegdall

University of Copenhagen

DENMARK
View details

Paul Timpson

Co-Director ACRF (INCITe) Centre

Garvan Institute of Medical Research

AUSTRALIA
View details

James D Brenton

University of Cambridge

UNITED KINGDOM
View details

Jae-Weon Kim

Professor

Seoul National University Hospital

SOUTH KOREA
View details

Cezary Cybulski

Pomeranian Medical University

POLAND
View details

Lyndal Anderson

University of Western Sydney

AUSTRALIA
View details

Claus Høgdall

Professor in Clinical Gynecologic Oncology

University of Copenhagen

DENMARK
View details

Lindsay J Collin

Assistant Professor

Emory University

UNITED STATES
View details

Jalid Sehouli

Charité - Universitätsmedizin Berlin

GERMANY
View details

Anthony Gill

University of Sydney

AUSTRALIA
View details

Linda Cook

Professor

University of Colorado Cancer Center

UNITED STATES
View details

Paul James

Head of Adult Genetics

The Royal Melbourne Hospital Royal Park Campus

AUSTRALIA
View details

Parham Minoo

Associate Clinical Professor of Pathology

University of Calgary

CANADA
View details

Angela Brooks-Wilson

Simon Fraser University

CANADA
View details

Tomasz Kluz

Professor

Rzeszów University

POLAND
View details

Joellen Schilkdraut

Professor

Emory University

UNITED STATES
View details

Michael Anglesio

Associate Professor

The University of British Columbia

CANADA
View details

Ramona Erber

W2-Professorin, Oberärztin

University of Regensburg

GERMANY
View details

Nicholas Hawkins

Emeritus Professor

UNSW Sydney

AUSTRALIA
View details

Usha Menon

Professor of Gynaecological Oncology

University College London

UNITED KINGDOM
View details

Sandra Orsulic

Professor

University of California, Los Angeles

UNITED STATES
View details

Cheng-Han Lee

Associate Professor

University of Alberta

CANADA
View details

Ian Campbell

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Stacey J. Winham

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Jae-Hoon Kim

Yonsei University College of Medicine

SOUTH KOREA
View details

Anna H. Wu

Professor

University of Southern California

UNITED STATES
View details

C Blake Gilks

-

CANADA
View details

Peter Fasching

-

GERMANY
View details

Francesmary Modugno

University of Pittsburgh

UNITED STATES
View details

Alexander Hein

-

GERMANY
View details

Kylie-Ann Mallitt

Senior Lecturer in Biostatistics

University of Sydney

AUSTRALIA
View details

Dale Garsed

University of Melbourne

AUSTRALIA
View details

Philip Crowe

Professor Surgery

University of New South Wales

AUSTRALIA
View details

Renée Fortner

Head of Division

Deutsches Krebsforschungszentrum

GERMANY
View details

K Sundfeldt

Professor/Consultant

University of Gothenburg, Sahlgrenska Academy

SWEDEN
View details

Tomasz Huzarski

Pomeranian Medical University

POLAND
View details

Byoung-Gie Kim

Sungkyunkwan University School of Medicine

SOUTH KOREA
View details

Dane Cheasley

Senior Research Fellow

University in Western Australia

AUSTRALIA
View details

Gregg Nelson

Gynecologic Oncologist

University of Calgary

CANADA
View details

Caroline X Gao

Associate Professor in Biostatistics

University of Melbourne

AUSTRALIA
View details

Jennifer Anne Doherty

Professor

University of Utah

UNITED STATES
View details

Paul Pharoah

Professor of Cancer Epidemiology

Cedars-Sinai Medical Center

UNITED STATES
View details

Brenda Y Hernandez

University of Hawaii

UNITED STATES
View details

Michael Edwin Jones

Senior Staff Scientist

Institute of Cancer Research

UNITED KINGDOM
View details

Kylie L Gorringe

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Jan Lubiński

Head of Dept

Pomeranian Medical University

POLAND
View details

Mona El-Bahrawy

Imperial College London

UNITED KINGDOM
View details

Aleksandra Gentry-Maharaj

University College London

UNITED KINGDOM
View details

David G. Huntsman

The University of British Columbia

CANADA
View details

Janusz Menkiszak

Head of the University Clinic

Pomeranian Medical University

POLAND
View details

Clare Scott

Walter and Eliza Hall Institute of Medical Research

AUSTRALIA
View details

Susan Ramus

Professor of Molecular Oncology

University of New South Wales

AUSTRALIA
View details

Paul Cohen

University of Western Australia

AUSTRALIA
View details

David Lawson Morris

Professor of Surgery

University of New South Wales

AUSTRALIA
View details